Pre-eclampsia
1
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Gedeon RichterHungary - Budapest
1 programPRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)N/A1 trial
Active Trials
Ferring PharmaceuticalsArgentina - Buenos Aires
1 programPRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)N/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Novartisrecombinant human relaxin
DiaMedica TherapeuticsDM199
Gedeon RichterPRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Angel PharmaceuticalsInduction of Labor
Clinical Trials (4)
Total enrollment: 480 patients across 4 trials
Evaluation of the Safety of Relaxin in Preeclampsia
Start: Oct 200618 patients
Phase 1Suspended
DM199 for Pregnancy Complications
Start: May 2025Est. completion: May 2025
N/AWithdrawn
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Start: Oct 2024Est. completion: Jun 2028462 patients
N/ARecruiting
Labor Induction in Preeclampsia High-risk Women
Start: Jan 2022Est. completion: Dec 2024
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 480 patients
5 companies competing in this space